Pliant Therapeutics - PLRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.11
  • Forecasted Upside: 35.10%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$34.87
▼ -1.39 (-3.83%)

This chart shows the closing price for PLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pliant Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLRX

Analyst Price Target is $47.11
▲ +35.10% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $47.11, with a high forecast of $55.00 and a low forecast of $33.00. The average price target represents a 35.10% upside from the last price of $34.87.

This chart shows the closing price for PLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Pliant Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023SVB LeerinkBoost TargetOutperform$33.00 ➝ $45.00Low
1/24/2023CitigroupBoost TargetBuy$36.00 ➝ $55.00Low
1/23/2023Needham & Company LLCBoost TargetBuy$40.00 ➝ $45.00Low
1/23/2023JPMorgan Chase & Co.Boost Target$42.00 ➝ $51.00Low
1/23/2023Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $52.00Low
12/13/2022Stifel NicolausInitiated CoverageBuy$33.00Low
12/7/2022JPMorgan Chase & Co.Initiated CoverageOverweight$42.00Low
11/9/2022Royal Bank of CanadaLower TargetOutperform$52.00 ➝ $50.00Low
9/1/2022CitigroupInitiated CoverageBuy$36.00Low
8/9/2022HC WainwrightBoost TargetBuy$45.00 ➝ $53.00Low
7/20/2022SVB LeerinkInitiated CoverageOutperform$33.00Low
7/11/2022Piper SandlerBoost Target$27.00 ➝ $40.00N/A
7/11/2022Cantor FitzgeraldBoost Target$28.00 ➝ $36.00N/A
7/11/2022Royal Bank of CanadaBoost Target$35.00 ➝ $54.00N/A
5/25/2022Cantor FitzgeraldInitiated CoverageOverweight$28.00High
5/17/2022Piper SandlerLower TargetOverweight$63.00 ➝ $27.00Medium
5/10/2022Needham & Company LLCReiterated RatingBuy$40.00Medium
12/9/2021OppenheimerInitiated CoverageOutperform$40.00High
11/23/2021Royal Bank of CanadaInitiated CoverageOutperform$38.00High
11/3/2021HC WainwrightInitiated CoverageBuy$45.00High
8/10/2021Needham & Company LLCInitiated CoverageBuy$40.00Medium
4/22/2021Piper SandlerBoost TargetOverweight$50.00 ➝ $63.00High
4/20/2021BTIG ResearchInitiated CoverageBuy$51.00Medium
4/5/2021CitigroupInitiated CoverageBuyLow
8/12/2020Needham & Company LLCReiterated RatingBuy$40.00High
6/29/2020CowenInitiated CoverageOutperformHigh
6/29/2020Needham & Company LLCInitiated CoverageBuy$40.00High
6/29/2020CitigroupInitiated CoverageBuy$40.00High
6/29/2020Piper SandlerInitiated CoverageOverweight$50.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 14 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/2/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/1/2022
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/30/2022
  • 13 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 13 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Pliant Therapeutics logo
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $34.87
Low: $34.87
High: $36.64

50 Day Range

MA: $20.95
Low: $17.00
High: $36.26

52 Week Range

Now: $34.87
Low: $3.96
High: $36.64

Volume

1,039,137 shs

Average Volume

1,508,763 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Pliant Therapeutics?

The following sell-side analysts have issued research reports on Pliant Therapeutics in the last year: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for PLRX.

What is the current price target for Pliant Therapeutics?

9 Wall Street analysts have set twelve-month price targets for Pliant Therapeutics in the last year. Their average twelve-month price target is $47.11, suggesting a possible upside of 35.1%. Citigroup Inc. has the highest price target set, predicting PLRX will reach $55.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $33.00 for Pliant Therapeutics in the next year.
View the latest price targets for PLRX.

What is the current consensus analyst rating for Pliant Therapeutics?

Pliant Therapeutics currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLRX will outperform the market and that investors should add to their positions of Pliant Therapeutics.
View the latest ratings for PLRX.

What other companies compete with Pliant Therapeutics?

How do I contact Pliant Therapeutics' investor relations team?

Pliant Therapeutics' physical mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-481-6770 and its investor relations email address is [email protected] The official website for Pliant Therapeutics is pliantrx.com. Learn More about contacing Pliant Therapeutics investor relations.